$0.65
7.96%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.71
-0.05 7.02% 1M
-0.32 31.07% 6M
+0.08 13.15% YTD
-1.26 63.96% 1Y
-12.09 94.45% 3Y
-30.71 97.74% 5Y
-167.36 99.58% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.03 4.41%
ISIN
US70387R1068
Symbol
PAVM
Sector

Key metrics

Market capitalization $12.14m
Enterprise Value $41.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.86
P/S ratio (TTM) P/S ratio 4.05
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 22.15%
Revenue (TTM) Revenue $3.00m
EBIT (operating result TTM) EBIT $-44.49m
Free Cash Flow (TTM) Free Cash Flow $-33.61m
Cash position $1.19m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 59.22
EV/Sales forward 202.88
Short interest 2.45%
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast PAVmed, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast PAVmed, Inc.:

Buy
100%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3 3
22% 22%
100%
- Direct Costs 6.04 6.04
35% 35%
201%
-3.04 -3.04
56% 56%
-101%
- Selling and Administrative Expenses 34 34
22% 22%
1,144%
- Research and Development Expense 5.93 5.93
60% 60%
198%
-43 -43
34% 34%
-1,443%
- Depreciation and Amortization 1.20 1.20
62% 62%
40%
EBIT (Operating Income) EBIT -44 -44
35% 35%
-1,483%
Net Profit 40 40
162% 162%
1,326%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
PRNewsWire
10 days ago
NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to th...
Neutral
PRNewsWire
12 days ago
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $1.20 per share. In addition, the Company...
Neutral
PRNewsWire
12 days ago
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 45-day option to purch...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 39
Founded 2014
Website www.pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today